

✓ -- THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40L)  
MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF  
VASCULITIS --

IN THE ABSTRACT\*

Please replace the Abstract with the following:

-- Activation of cells bearing CD40 on their surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting the interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells are treated, in particular vasculitis. --

IN THE CLAIMS\*

Please cancel claims 1 and 102 to 144, without prejudice.

Please add claims 145 to 166 as follows:

C2 145. (added) A method for treating vasculitis in a human, other than a transplant recipient, comprising the step of administering to said human an antibody, Fab, F(ab)'2 or a single chain antibody, which binds specifically to an antigen specifically bound by monoclonal antibody 5c8, produced by the hybridoma having ATCC Accession No. HB 10916, wherein said

\*The amendments to the Title and Abstract, are indicated in the Appendix hereto (Exhibit A) for the Examiner's convenience. The added claims are also set forth in the Appendix.